NCT00222534

Acetazolamide for Respiratory Failure in Combination With Metabolic Alkalosis

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 70 (actual)
• Sponsor: University of Oslo School of Pharmacy · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Respiratory failure is a common consequence of chronic obstructive pulmonary disease (COPD). A concurrent metabolic alkalosis may worsen the respiratory failure, as a higher pH in blood (and thus in cerebrospinal fluid) results in a weaker respiratory drive. Use of diuretics is the most common cause of metabolic alkalosis. When a patient with an acute exacerbation of a respiratory failure is also alkalotic, there are (at least theoretical) reasons to lower the pH in order to increase the respiratory drive. Among other alternatives, the drug acetazolamide can be used for this purpose. In some hospitals there is a tradition for the use of acetazolamide on this indication, but any evidence for the effect of such a treatment is rather weak. Thus, the aim of this trial is to evaluate the effect of acetazolamide as an adjuvant treatment for hospitalized patients with acute exacerbation of respiratory failure in combination with metabolic alkalosis.

Conditions

• Respiratory Insufficiency
• Alkalosis

Interventions

Type	Name	Description
DRUG	Acetazolamide
DRUG	Placebo

Timeline

• Start date: 2002-01-01
• Primary completion: 2009-12-01
• Completion: 2009-12-01
• First posted: 2005-09-22
• Last updated: 2014-01-20

Locations

5 sites across 1 country: Norway